BDX vs OMCL
BDX: BD is a leading global medical technology company providing essential medical devices, diagnostic systems, and laboratory solutions to healthcare providers and researchers worldwide. OMCL: Omnicell automates medication management across healthcare settings through storage, dispensing, and intelligence solutions to enable safer, more efficient pharmacy operations.
Side-by-side fundamentals
| Metric | BDX | OMCL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $153.16 | $40.86 | |
| Market cap as of 2026-07-23 | $42.2B | $1.9B | |
| P/E as of 2026-07-23 | 37.10 | 91.01 | BDX lower |
| PEG as of 2026-07-23 | -20.92 | 2.94 | BDX lower |
| Net margin as of 2026-07-23 | +5.3% | +1.7% | BDX higher |
| Gross margin as of 2026-07-23 | +47.0% | +43.5% | BDX higher |
| Operating margin as of 2026-07-23 | +10.2% | +2.8% | BDX higher |
| ROE as of 2026-07-23 | +4.5% | +1.6% | BDX higher |
| ROA as of 2026-07-23 | +2.1% | +1.0% | BDX higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.13 | OMCL lower |
| Revenue growth (YoY) as of 2026-07-23 | +2.4% | +7.9% | OMCL higher |
| Revenue CAGR (3y) SEC XBRL | +5.0% | -2.9% | BDX higher |
| Dividend yield as of 2026-07-23 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.21 | 0.97 | |
| 1-year return as of 2026-07-22 close | +7.5% | +44.6% | OMCL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.